https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45027 HFE, TFR1, HAMP, TF, SOD2, CAT and GPX1. Results: Lung cancer patients compared to their matched controls had significantly higher mean serum iron level (p = 0.01), ferritin level (p = 0.007) and TIBC (p = 0.006). Analysis revealed that higher concentration of iron and ferritin (IVth quartile) compared to the lower concentration (Ist quartile) was associated with over 2-fold increased lung cancer incidence. We also found that higher transferrin saturation (p = 0.01) and lower TIBC (p<0.01) are associated with better survival of lung cancer patients. The analysis of polymorphisms in iron related genes did not reveal a significant difference between lung cancer patients and controls. However, rs10421768 in HAMP showed a borderline statistically significant correlation with lung cancer risk (OR = 2.83, p = 0.05). Conclusions: The results of this case control study indicate that higher body iron represented by higher Fe and ferritin levels may be associated with lung cancer incidence. Rs10421768 in HAMP may be associated with about 3-times higher lung cancer risk. Higher Fe body content may be associated with better survival of lung cancer patients]]> Wed 26 Oct 2022 11:09:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32834 Wed 19 Jan 2022 15:17:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36717 Thu 09 Dec 2021 11:03:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33626 Thu 03 Feb 2022 12:22:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32848 Mon 23 Sep 2019 12:46:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37952 Mon 05 Jul 2021 19:32:56 AEST ]]>